NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies

Neurobiology of Aging

Volumn 28, Issue 5, 2007, Pages 639-647

  McGeer, Patrick L ^a   McGeer, Edith G ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Activated microglia; Amyloid; COX 1; COX 2; Inflammation; Neurofibrillary tangles; Transgenic mice

Indexed keywords

ACETYLSALICYLIC ACID; ARTHROTEC; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; NAPROXEN; NCX 2216; NIMESULIDE; NIMUSELIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PIOGLITAZONE; ROFECOXIB; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CLINICAL STUDY; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE MODEL; DOSE RESPONSE; GASTROINTESTINAL SYMPTOM; HUMAN; INFLAMMATION; MICROGLIA; NONHUMAN; PATHOLOGY; PILOT STUDY; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DISEASE MODELS, ANIMAL; HUMANS;

EID: 33847339301     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2006.03.013     Document Type: Review

References (70)

1. Aisen P.S., Schafer K.A., Grundman M., Pfeiffer E., Sano M., Davis K.L., et al. Effects of rofecoxib or naproxen vs. placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 289 (2003) 2819-2826
2. Aisen P.S., Schmeidler J., and Pasinetti G.M. Randomized pilot study of nimesulide treatment in Alzheimer's disease. Neurology 58 (2002) 1050-1054
3. Anon. The Canadian Study of Health and Aging: risk factors for Alzheimer's disease in Canada. Neurology 44 (1994) 2073-2080
4. Anthony J.C., Breitner J.C., Zandi P.P., Meyer M.R., Jurasova I., Norton M.C., et al. Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study. Neurology 54 (2000) 2066-2071
5. Beard C.M., Waring S.C., O'Brien P.C., Kurland L.T., and Kokmen E. Nonsteroidal anti-inflammatory drug use and Alzheimer's disease: a case-control study in Rochester, Minnesota, 1980 through 1984. Mayo Clin Proc 73 (1998) 951-955
6. Breitner J.C., Gau B.A., Welsh K.A., Plassman B.L., McDonald W.M., Helms M.J., et al. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology 44 (1994) 227-232
7. Breitner J.C., Welsh K.A., Helms M.J., Gaskell P.C., Gau B.A., Roses A.D., et al. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging 16 (1995) 523-530
8. Broe G.A., Grayson D.A., Creasey H.M., Waite L.M., Casey B.J., Bennett H.P., et al. Anti-inflammatory drugs protect against Alzheimer disease at low doses. Arch Neurol 57 (2000) 1586-1591
9. de Craen A.J., Gussekloo J., Vrijsen B., and Westendorp R.G. Meta-analysis of nonsteroidal antiinflammatory drug use and risk of dementia. Am J Epidemiol 161 (2005) 114-120
10. Duff K., Echman C., Zehr C., Yu X., Prada C.M., Perez-tur J., et al. Increased amyloid-b42(43) in brains of mice overexpressing mutant presenilin-1. Nature 383 (1996) 710-713
11. Etminan M., Gill S., and Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ 327 (2003) 128
12. Firuzi O., and Pratico D. Coxibs and Alzheimer's disease: should they stay or should they go?. Ann Neurol 59 (2006) 219-228
13. Fourrier A., Letenneur L., Begaud B., and Dartigues J.F. Nonsteroidal antiinflammatory drug use and cognitive function in the elderly: inconclusive results from a population-based cohort study. J Clin Epidemiol 49 (1996) 1201
14. Hanlon J.T., Schmader K.E., Landerman L.R., Horner R.D., Fillenbaum G.G., Pieper C.F., et al. Relation of prescription nonsteroidal antiinflammatory drug use to cognitive function among community-dwelling elderly. Ann Epidemiol 7 (1997) 87-94
15. Hee K.J., and Grodstein F. Regular use of nonsteroidal anti-inflammatory drugs and cognitive function in aging women. Neurology 60 (2003) 1591-1597
16. Henderson A.S., Jorm A.F., Christensen H., Jacomb P.A., and Korten A.E. Aspirin, anti-inflammatory drugs and risk of dementia. Int J Geriatr Psychiat 12 (1997) 926-930
17. Heneka M.T., Sastre M., Dumitrescu-Ozimek L., Hanke A., Dewachter I., Kuiperi C., et al. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 128 (2005) 1442-1453
18. Hoozemans J.J.M., Veerhuis R., Janssen I., van Elk E.J., Rozemuller A.J.M., and Eikelenboom P. The role of cyclo-oxygenase 1 and 2 activity in prostaglandin E-2 secretion by cultured human adult microglia: implications for Alzheimer's disease. Brain Res 951 (2002) 218-226
19. Hoozemans J.J.M., Veerhuis R., Rozemuller A.J.M., and Eikelenboom P. Non-steroidal anti-inflammatory drugs and cyclooxygenase in Alzheimer's disease. Curr Drug Targets 4 (2003) 461-468
20. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin F., et al. Correlative memory deficits, Abeta elevation and amyloid plaques in transgenic mice. Science 274 (1996) 99-102
21. in't Veld B.A., Ruitenberg A., Hofman A., Launer L.J., van Duijn C.M., Stijnen T., et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. New Engl J Med 345 (2001) 1515-1521
22. Jantzen P.T., Connor K.E., DiCarlo G., Wenk G.L., Wallace J.L., Rojiani A.M., et al. Microglial activation and beta-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci 22 (2002) 2246-2254
23. Jarvenpaa T., Raiha I., Kaprio J., Koskenvuo M., Laine M., Kurki T., et al. A 90-year-old monozygotic female twin pair discordant for Alzheimer's disease. Neurobiol Aging 24 (2003) 941-945
24. Jonker C., Comijs H.C., and Smit J.H. Does aspirin or other NSAIDs reduce the risk of cognitive decline in elderly persons? Results from a population-based study. Neurobiol Aging 24 (2003) 583-588
25. Kaufmann W.E., Andreasson K.I., Isakson P.C., and Worley P.F. Cyclooxygenases and the central nervous system. Prostaglandins 54 (1997) 601-624
26. Klegeris A., and McGeer P.L. Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents in the treatment of neurodegenerative disease. Curr Alz Res 2 (2005) 355-365
27. Klegeris A., Walker D.G., and McGeer P.L. Toxicity of human THP-1 monocytic cells towards neuron-like cells is reduced by non-steroidal anti-inflammatory drugs (NSAIDs). Neuropharmacology 38 (1999) 1017-1025
28. Kukar T., Murphy M.P., Eriksen J.L., Sagi S.A., Weggen S., Smith T.E., et al. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Ab42 production. Nature Med 11 (2005) 545-550
29. Landi F., Cesari M., Onder G., Russo A., Torre S., and Bernabei R. Non-steroidal anti-inflammatory drug (NSAID) use and Alzheimer disease in community-dwelling elderly patients. Am J Geriatr Psychiat 11 (2003) 179-185
30. Lehmann J.M., Lenhard J.M., Oliver B.B., Ringold G.M., and Kliewer S.A. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 272 (1997) 3406-3410
31. Lim G.P., Yang F., Chu T., Chen P., Beech W., Teter B., et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 20 (2000) 5709-5714
32. Lim G.P., Yang F., Chu T., Gahtan E., Ubeda O., Beech W., et al. Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol Aging 22 (2001) 983-991
33. Lindsay J., Laurin D., Verreault R., Hebert R., Helliwell B., Hill G.B., et al. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol 156 (2002) 445-453
34. Mackenzie I.R.A. Anti-inflammatory drugs and Alzheimer-type pathology in aging. Neurology 54 (2000) 732-734
35. May F.E., Moore M.T., Stewart R.B., and Hale W.E. Lack of association of nonsteroidal anti-inflammatory drug use and cognitive decline in the elderly. Gerontology 38 (1992) 275-279
36. McGeer P.L., Itagaki S., Tago H., and McGeer E.G. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Lett 79 (1987) 195-200
37. McGeer P.L., and McGeer E.G. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev 21 (1995) 195-218
38. McGeer P.L., and McGeer E.G. Inflammation and the degenerative diseases of aging. Ann N Y Acad Sci 1035 (2004) 104-116
39. McGeer P.L., McGeer E., Rogers J., and Sibley J. Anti-inflammatory drugs and Alzheimer disease. Lancet 335 (1990) 1037
40. McGeer P.L., and Rogers J. Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease. Neurology 42 (1992) 447-449
41. McGeer P.L., Schulzer M., and McGeer E.G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 47 (1996) 425-432
42. McGeer P.L., Walker D.G., Akiyama H., Kawamata T., Guan A.L., Parker C.J., et al. Detection of the membrane inhibitor of reactive lysis (CD59) in diseased neurons of Alzheimer brain. Brain Res 544 (1991) 315-319
43. Moechars D., Dewachter I., Lorent K., Reverse D., Baekelandt V., Naidu A., et al. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem 274 (1999) 6483-6492
44. Neuroinflammation Working Group. Inflammation and Alzheimer's disease. Neurobiol Aging 21 (2000) 383-421
45. Nilsson S.E., Johansson B., Takkinen S., Berg S., Zarit S., McClearn G., et al. Does aspirin protect against Alzheimer's dementia? A study in a Swedish population-based sample aged > or =80 years. Eur J Clin Pharmacol 59 (2003) 313-319
46. Quinn J., Montine T., Morrow J., Woodward W.R., Kulhanek D., and Eckenstein F. Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease. J Neuroimmunol 137 (2003) 32-41
47. Reines S.A., Block G.A., Morris J.C., Liu G., Nessly M.L., Lines C.R., et al. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 62 (2004) 66-71
48. Rogers J., Cooper N.R., Webster S., Schultz J., McGeer P.L., Styren S.D., et al. Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci USA 89 (1992) 10016-10020
49. Rogers J., Luber-Narod J., Styren S.D., and Civin W.H. Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease. Neurobiol Aging 9 (1988) 339-349
50. Rogers J., Kirby L.C., Hempelman S.R., Berry D.L., McGeer P.L., Kaszniak A.W., et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 43 (1993) 1609-1611
51. Rozzini R., Ferrucci L., Losonczy K., Havlik R.J., and Guralnik J.M. Protective effect of chronic NSAID use on cognitive decline in older persons. J Am Geriatr Soc 44 (1996) 1025-1029
52. Saag K.G., Rubenstein L.M., Chrischilles E.A., and Wallace R.B. Nonsteroidal antiinflammatory drugs and cognitive decline in the elderly. J Rheumatol 22 (1995) 2142-2147
53. Sainati S.M., Ingram D.M., Talwalker S., and Geis G.S. Results of a double-blind, placebo-controlled study of celecoxib for the progression of Alzheimer's disease. Proceedings of the sixth International Stockholm-Springfield Symposium of advances in Alzheimer therapy (2000) 180
54. Scharf S., Mander A., Ugoni A., Vajda F., and Christophidis N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 53 (1999) 197-201
55. Seibert K., Zhang Y., Leahy K., Hauser S., Masferrer J., Perkins W., et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 91 (1994) 12013-12017
56. Stewart W.F., Kawas C., Corrada M., and Metter E.J. Risk of Alzheimer's disease and duration of NSAID use. Neurology 48 (1997) 626-632
57. Sturmer T., Glynn R.J., Field T.S., Taylor J.O., and Hennekens C.H. Aspirin use and cognitive function in the elderly. Am J Epidemiol 143 (1996) 683-691
58. Sung J.J.Y., Russell R.I., Yeomans N., Chan F.K.L., Chen S.L., Fock K., et al. Non-steroidal anti-inflammatory drug toxicity in the upper gastrointestinal tract. J Gastro Hepatol 15 (2000) G58-G68
59. Sung S., Yang H., Uryu K., Lee E.B., Zhao L., Shineman D., et al. Modulation of nuclear factor-kB activity by indomethacin influences Ab levels but not Ab precursor protein metabolism in a model of Alzheimer's disease. Am J Pathol 165 (2004) 2197-2206
60. Szekely C.A., Thorne J.E., Zandi P.P., Ek M., Messias E., Breitner J.C., et al. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 23 (2004) 159-169
61. van Groen T., and Kadish I. Transgenic AD model mice, effects of potential anti-AD treatments on inflammation and pathology. Brain Res Rev 48 (2005) 370-378
62. Wallace J.L., Reuter B., Cicala C., McKnight W., Grisham M.B., and Cirino G. Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology 107 (1994) 173-179
63. Webster S., Lue L.F., Brachova L., Tenner A.J., McGeer P.L., Terai K., et al. Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease. Neurobiol Aging 18 (1997) 415-421
64. Weggen S., Eriksen J.L., Das P., Sagi S.A., Wang R., Pietrzik C.U., et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414 (2001) 212-216
65. Wolfson C., Perrault A., Moride Y., Esdaile J.M., Abenhaim L., and Momoli F. A case-control analysis of nonsteroidal anti-inflammatory drugs and Alzheimer's disease: are they protective?. Neuroepidemiology 21 (2002) 81-86
66. Yan Q., Zhang J., Liu H., Babu-Khan S., Vassar R., Biere A.L., et al. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci 23 (2003) 7504-7509
67. Yasojima K., Schwab C., McGeer E.G., and McGeer P.L. Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs. Brain Res 830 (1999) 226-236
68. Yermakova A.V., Rollins J., Callahan L.M., Rogers J., and O'Banion M.K. Cyclooxygenase-1 in human Alzheimer and control brain: quantitative analysis of expression by microglia and CA3 hippocampal neurons. J Neuropathol Exp Neurol 58 (1999) 1135-1146
69. Yip A.G., Green R.C., Huyck M., Cupples L.A., and Farrer L.A. Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: the MIRAGE study. BMC Geriatr 5 (2005) 2
70. Zandi P.P., Anthony J.C., Hayden K.M., Mehta K., Mayer L., and Breitner J.C. Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County study. Neurology 59 (2002) 880-886